Table 6.
Comparative effectiveness on American College of Rheumatology 70 response
| Treatment | No. of studies | No. of participants | OR (95% CrI) | Best | Probability OR (mean) |
|---|---|---|---|---|---|
| MTX (placebo + MTX) | 10 | 1,289 | - | 0 | - |
| CERT + MTX | 2 | 786 | 10.460 (3.660–24.410) | 0.3671 | 0.9990 |
| ADAL | 1 | 67 | 13.300 (1.708–52.970) | 0.3602 | 0.9922 |
| ADAL + MTX | 2 | 274 | 8.086 (2.762–19.650) | 0.1599 | 0.9985 |
| GOL | 1 | 133 | 3.422 (0.624–10.370) | 0.0131 | 0.9276 |
| GOL + MTX | 4 | 608 | 6.917 (3.137–15.250) | 0.0703 | 0.9997 |
| IFX + MTX | 2 | 293 | 4.084 (0.939–11.670) | 0.0153 | 0.9713 |
| MTX + HCQ + SSZ | 1 | 130 | 3.457 (0.283–10.940) | 0.0141 | 0.7695 |
OR, odds ratio; CrI, credible interval (the probability to include a parameter); MTX, methotrexate; CERT, certolizumab; ADAL, adalimumab; GOL, golimumab; IFX, infliximab; HCQ, hydroxychloroquine; SSZ, sulfasalazine.